ArticleCancer biology & therapy2025
RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma.
Article in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of a novel PANoptosis-associated prognostic signature and immune landscape analysis in neuroblastoma with experimental validation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma (MM) features plasma cell (PC) heterogeneity and alterations in B-cell differentiation and immune regulation. Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear.
methodsWe performed CyTOF profiling on bone marrow samples from RVd- (
resultsRVd and CyBorD therapies exerted distinct immune modulation patterns, differentially affecting PC, early B-cell stages, and naive T cells. Evaluation of transcriptional B-cell regulators in B-cell lymphopoiesis revealed that both regimens decreased IRF4, CXCR4, and FGFR3 while upregulating Pax-5 across B-cell stages and PC. RVd uniquely upregulated MYD88 and c-Myc and decreased sXBP1; its responders further suppressed BLIMP-1 and FGFR3. In contrast, CyBorD elevated sXBP1, BLIMP-1, and Notch-1 while reducing c-Myc in the B and PC subsets. Both therapies increased the expression of the stemness factor KLF4 and variably modulated NANOG; CyBorD altered Nestin and RARα2 in responder PCs, whereas RVd suppressed OCT3/4. Shared immunophenotypic aberrations included decreased MMSET, CD200, and CD52, and increased CD47, CD81, and CD44 in B-cell compartments. In PC, both regimens elevated CD338 while reducing CD47, CD319, and CD138. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243.
conclusionsThese shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.